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IMPORTANCE The prognostic impact of DNA mismatch repair (MMR) status in stage III colon
cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant
chemotherapy remains controversial.
OBJECTIVE To determine the association of MMR status with disease-free survival (DFS) in
patients with stage III colon cancer treated with FOLFOX.
DESIGN, SETTING, AND PARTICIPANTS The evaluated biomarkers for MMR status were
determined from prospectively collected tumor blocks from patients treated with FOLFOX
in 2 open-label, phase 3 randomized clinical trials: NCCTG N0147 and PETACC8. The studies
were conducted in general community practices, private practices, and institutional practices
in the United States and Europe. All participants had stage III colon adenocarcinoma. They
were enrolled in NCCTG N0147 from February 2004 to November 2009 and in PETACC8
from December 2005 to November 2009.
INTERVENTIONS Patients in the clinical trials were randomly assigned to receive 6 months
of chemotherapy with FOLFOX or FOLFOX plus cetuximab. Only those patients treated with
FOLFOX alone were included in the present study.
MAIN OUTCOMES AND MEASURES Association of MMR status with DFS was analyzed using
a stratified Cox proportional hazards model. Multivariable models were adjusted for age, sex,
tumor grade, pT/pN stage, tumor location, ECOG (Eastern Cooperative Oncology Group)
performance status, and BRAF V600E mutational status.
RESULTS Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status
was available for 2501. Of these, 252 (10.1%) showed deficient MMR status (dMMR; 134
women, 118 men; median age, 59 years), while 2249 (89.9%) showed proficient MMR status
(pMMR; 1020 women, 1229 men; median age, 59 years). The 3-year DFS rates in the dMMR
and pMMR groups were 75.6% and 74.4%, respectively. By multivariate analysis, patients
with dMMR phenotype had significantly longer DFS than those with pMMR (adjusted hazard
ratio, 0.73; 95% CI, 0.54-0.97; P = .03).
CONCLUSIONS AND RELEVANCE The deficient MMR phenotype remains a favorable prognostic
factor in patients with stage III colon cancer receiving FOLFOX adjuvant chemotherapy.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00079274 for the NCCTG N0147 trial
and EudraCT identifier: 2005-003463-23 for the PETACC8 trial.
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A djuvant trials have demonstrated that adding oxalipl-atin to fluorouracil is associated with improvement insurvival of patients with stage III colon cancer, thereby
establishing FOLFOX (folinic acid, fluorouracil, and oxalipl-
atin) as the current standard of care.1 A subset of colorectal can-
cer (CRC) displays a microsatellite instability (MSI) pheno-
type that is the consequence of deficient DNA mismatch repair
(dMMR), due either to a germline mutation in an MMR gene,
producing Lynch syndrome, or, more commonly, to epigen-
etic inactivation of the MLH1 gene (OMIM 120436) in spo-
radic cases.2 Somatic mutations in BRAF V600E are enriched
in sporadic dMMR subtypes in contrast to a low frequency in
CRCs overall.3
While most studies have found that patients with dMMR
(vs proficient MMR [pMMR]) tumors have a more favorable
stage-adjusted prognosis,4 other studies have not detected a
significant difference in clinical outcome5 or have suggested
that any favorable prognostic effect of dMMR is limited to pa-
tients with earlier-stage tumors.6 Furthermore, studies have
shown that dMMR tumors may not benefit from fluorouracil-
based adjuvant chemotherapy.4 However, the impact of MMR
status remains controversial in the era of the standard FOLFOX
adjuvant chemotherapy.
In a pooled analysis, we examined the association of MMR
status with disease-free survival (DFS) in patients with stage
III colon cancer treated with FOLFOX from 2 phase 3 random-
ized clinical trials: the trial of the North Central Cancer Treat-
ment Group (NCCTG, now part of the Alliance for Clinical Trials




This pooled analysis included all patient participants in the
NCCTG N01477 and PETACC88 adjuvant randomized phase 3
trials who had signed biological informed consent and
whose tumor blocks of resected stage III colon adenocarci-
noma were available for analysis. Patients were randomized
after surgery to receive 6 months of adjuvant FOLFOX
therapy w ith or w ithout cetuximab, as desc ribed
previously.7,8 The present study is restricted to patients
treated with FOLFOX alone, since the cetuximab did not
improve efficacy in adjuvant setting.7,8 The NCCTG N0147
trial (NCT00079274) enrolled participants between February
2004 and November 2009; the PETACC8 trial (EudraCT 2005-
003463-23) enrolled participants between December 2005 and
November 2009. The molecular analysis was centralized at the
Mayo Clinic, Rochester, Minnesota, for the NCCTG N0147 trial,
and at the European Georges Pompidou Hospital, Paris, France,
for the PETACC8 trial.
MMR Status Determination
Mismatch repair (MMR) tumor status was determined by im-
munohistochemical analysis (IHC) or by MSI testing when IHC
findings were indeterminate, as previously described for each
trial.9,10 Tumors with a dMMR phenotype were defined as
showing loss of expression of 1 or more MMR proteins by IHC
or exhibiting high-level tumor DNA MSI on MSI testing by poly-
merase chain reaction (PCR). Proficient MMR phenotype tu-
mors were defined as showing intact MMR protein expres-
sion on IHC or microsatellite-stable or low-level MSI status on
MSI testing.
DNA Extraction and Mutation Analysis
Tumor DNA was extracted from formalin-fixed, paraffin-
embedded tissue specimens containing more than 50% tu-
mor cells using the QIAamp DNA Mini Kit (Qiagen). Testing for
the BRAF V600E hotspot exon 15 mutation (c.1799T>A/
p.V600E) and KRAS exon 2 mutation was performed as de-
scribed previously.9,10
Statistical Analysis
Biomarker status data were analyzed with investigators blinded
to patient outcomes. We defined DFS as the time between ran-
domization and local or metastatic recurrence, or death from
any cause, whichever occurred first.
For comparisons of baseline characteristics, categorical fac-
tors were analyzed with χ2 tests, and continuous factors were
compared with Wilcoxon rank-sum tests. A stratified Cox re-
gression model was used to estimate hazard ratios (HRs) and
95% confidence intervals (CIs) and to calculate P values for can-
didate prognostic factors.
Thereafter, multivariable analyses were performed on
MMR phenotype adjusted for patient age, sex, tumor grade,
ECOG (Eastern Cooperative Oncology Group) performance sta-
tus, pT/pN stage, primary tumor location, and BRAF V600E
mutational status. Survival curves were estimated with
the Kaplan-Meier method and adjusted for the reported
covariates.11 Discriminatory accuracy was tested using the
Harrell concordance index. The Harrell c index was used to
estimate the proportion of correct predictions. The Harrell
c index ranges from 0.5 (no discrimination) to 1 (perfect
discrimination).
Two-sided P values are reported; P < .05 was considered
statistically significant. Analyses were performed using SAS
software, version 9.4 (SAS Institute Inc), on a data set locked
on June 2015. Data collection and statistical analyses were
conducted by the Alliance Statistics and Data Center.
Key Points
Question What is the role of deficient DNA mismatch repair
(MMR) in stage III colon cancer in the era of standard FOLFOX
(folinic acid, fluorouracil, and oxaliplatin) adjuvant
chemotherapy?
Findings This pooled multivariable analysis of data from
2 randomized clinical trials revealed that deficient vs proficient
MMR was significantly associated with longer disease-free survival
in patients with stage III colon cancer who were treated with
FOLFOX alone.
Meanings Future clinical trials in the adjuvant setting should
consider MMR status as an important stratification factor.
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Results
Patients
Among 2636 patients with stage III colon cancer treated with
FOLFOX alone in the NCCTG N0147 (n = 1669)7 and
PETACC88 (n = 967) adjuvant therapy trials, MMR status was
available for 2501 patients. Among this study population,
10.1% (252 of 2501) of tumors showed a dMMR phenotype
(Figure 1). Consistent with prior studies, and with all sup-
porting data reported in the Table, dMMR vs pMMR was
significantly associated with older age, female sex, higher
T stage, higher tumor grade, and proximal location.4 As
expected, mutations of BRAF V600E were more often asso-
ciated with dMMR (36.9%) than with pMMR (6.3%) tumors
(P < .001) (Table).6,12 The overall median follow-up was
4.0 years (interquartile range, 3.3-5.0 years).
Figure 1. Participant Enrollment Flowchart
2636 Patients treated with FOLFOX alone
from NCCTG N0147 and PETACC8
2501 Patients tested for MMR status
2249 Proficient MMR 252 Deficient MMR




Included are participants in the NCCTG N01477 and PETACC88 phase 3 trials
evaluating the impact of mismatch repair (MMR) phenotype in patients with
stage III colon cancer treated with FOLFOX (folinic acid, fluorouracil, and
oxaliplatin) adjuvant chemotherapy.
Table. Demographic and Clinicopathologic Characteristics of Stage III Colon Cancer Patients Treated
With FOLFOX Arm From NCCTG N0147 and PETACC8 Trials
Characteristic








<70 208 (82.5) 1977 (87.9) .01
≥70 44 (17.5) 272 (12.1)
Sex .02
Female 134 (53.2) 1020 (45.4)
Male 118 (46.8) 1229 (54.6)
ECOG PS .42
0 192 (78.0) 1773 (79.8)
1 54 (22.0) 439 (19.8)
≥2 0 (0.0) 10 (0.5)
pT stage .01
pT1-pT2 19 (7.5) 310 (13.8)
pT3 185 (73.4) 1598 (71.1)
pT4 48 (19.0) 341 (15.2)
pN stage .27
pN1 160 (63.5) 1347 (59.9)
pN2 92 (36.5) 902 (40.1)
Tumor grade <.001
High 121 (48.4) 439 (19.6)
Low 129 (51.6) 1800 (80.4)
Tumor site <.001
Proximal 213 (86.2) 896 (40.5)
Distal 34 (13.8) 1314 (59.5)
KRAS exon 2 status <.001
Wild-type 192 (77.1) 1289 (57.9)
Mutated 57 (22.9) 937 (42.1)
BRAF V600E status <.001
Wild-type 152 (63.1) 1994 (93.7)
Mutated 89 (36.9) 133 (6.3)
Abbreviations: dMMR, deficient
MMR; ECOG PS, Eastern Cooperative
Oncology Group performance status;
MMR, Mismatch Repair;
pMMR, proficient MMR.
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Association of MMR Status and Clinical Outcome
In this study population of patients with stage III colon can-
cer treated with FOLFOX, there were 701 recurrences and 415
deaths. The 3-year DFS rates in dMMR and pMMR tumors were
75.6% and 74.4%, respectively. In multivariate analysis that in-
cluded BRAF V600E mutational status, compared with the
pMMR group, patients with dMMR tumor had a significantly
longer DFS (adjusted HR, 0.73; 95% CI, 0.54-0.97; P = .03)
(Harrell c index, 0.67; 95% CI, 0.64-0.70) (Figure 2).
Discussion
In the era of FOLFOX adjuvant chemotherapy, the first data
concerning the impact of MMR status came from retrospec-
tive studies suggesting that the addition of oxaliplatin to
fluorouracil may confer survival benefit for patients with
stage III dMMR colon cancer.13,14 Thereafter, post hoc analy-
ses of patients with stage II and III colon cancer (n = 1796)
from NSABP-C07 (comparing fluorouracil with and without
oxaliplatin) and NSABP-C08 (comparing FOLFOX with and
without bevacizumab) trials suggested that the benefit of
adding oxaliplatin to fluorouracil was independent of MMR
status.12 Similarly, the analysis of MMR status in patients
with stage II and III colon cancer (n = 1008) from the
MOSAIC trial suggested that patients with both dMMR and
pMMR tumors had a survival benefit from FOLFOX com-
pared with fluorouracil alone, although the number of
dMMR tumors analyzed was limited.15
In the present pooled analysis of patients with stage III co-
lon cancer treated with FOLFOX in 2 adjuvant trials, we found
that the dMMR phenotype was a favorable prognostic factor.
Although the Harrell c index is of marginal clinical utility
(<0.70), our study has several strengths that include prospec-
tive tissue biospecimen collection and uniform tumor stage (III
only) and treatment of patients enrolled in large recent ran-
domized studies. Our report represents the largest study to date
evaluating the relationship of MMR status with clinical out-
come for FOLFOX adjuvant treatment. The relatively low ben-
efit in terms of 3-year DFS rates (75.6% vs 74.4%) associated
with a significant decrease in the risk of recurrence in multi-
variate analysis (HR, 0.74) is related to the fact that our study
is a post hoc and unplanned analysis with imbalanced sub-
groups of patients (Table). Therefore, the unadjusted analy-
sis highlights a survival benefit that may appear to be low but
is actually clinically meaningful based on multivariate analy-
sis that adjusts the results on clinical and pathological char-
acteristics of these two groups.
Limitations
The main study limitation is the lack of mature follow-up to
assess the overall survival.
Conclusions
In conclusion, this large pooled analysis showed that dMMR
is a favorable prognostic factor in patients with stage III colon
cancer treated with FOLFOX adjuvant chemotherapy. Future
clinical trials in the adjuvant setting should consider this
molecular characteristic as an important stratification factor.
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Disease-free survival by MMR phenotype, deficient (dMMR) vs proficient
(pMMR), in patients with stage III colon cancer treated with adjuvant FOLFOX
(folinic acid, fluorouracil, and oxaliplatin). Survival curves and hazard ratio (HR)
with 95% confidence intervals (CIs) are adjusted for age, sex, tumor grade,
ECOG (Eastern Cooperative Oncology Group) performance status, pT/pN stage,
primary tumor location, and BRAF V600E mutational status.
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